Treatment Overview
Induction BCG (Bacillus Calmette-Guérin) therapy is the initial phase of immunotherapy for non-muscle invasive bladder cancer (NMIBC). It involves delivering BCG, a weakened strain of Mycobacterium bovis, directly into the bladder through a catheter to stimulate the immune system to attack cancer cells. Korea is internationally recognized for its expertise in BCG induction therapy, offering precise dosing, advanced cystoscopic guidance, and comprehensive monitoring to maximize treatment effectiveness while minimizing side effects. Hospitals often combine induction therapy with TURBT (transurethral resection of bladder tumor) to ensure complete tumor management.
Purpose & Benefits
The primary purpose of induction BCG therapy is to eradicate residual cancer cells after TURBT and reduce the risk of tumor recurrence. Benefits include:
- Strong localized immune response against bladder cancer cells
- Prevention of progression to muscle-invasive disease
- Preservation of bladder function and quality of life
- Outpatient-based procedure with minimal systemic effects
- Foundation for subsequent maintenance BCG therapy for long-term protection
Korean hospitals tailor induction therapy schedules to tumor stage, grade, and patient-specific factors for maximum effectiveness.
Ideal Candidates
Ideal candidates for induction BCG therapy include:
- Patients with high-risk NMIBC, including carcinoma in situ (CIS)
- Individuals who have undergone TURBT but remain at high risk for recurrence
- Patients seeking bladder preservation over radical surgery
- Those medically suitable for intravesical immunotherapy
Patients with active urinary infections, immune deficiencies, or bladder perforation require careful evaluation. Korean urologists conduct thorough pre-treatment assessments to ensure suitability.
Possible Risks & Complications
Induction BCG therapy is generally safe, but potential side effects include:
- Bladder irritation, urgency, and frequency
- Painful urination (dysuria)
- Hematuria (blood in urine)
- Fever or flu-like symptoms
- Rare systemic infection if BCG bacteria spread
- Bladder contracture in rare long-term cases
Korean hospitals implement careful dosing, monitoring, and patient education to reduce risks and manage side effects effectively.
Techniques & Technology Used
Advanced techniques in Korea enhance induction BCG therapy outcomes:
- Cystoscopic-guided catheterization for accurate intravesical drug delivery
- Standardized induction schedules, usually weekly for 6 weeks
- Combination with TURBT for optimal tumor removal
- Regular urine cytology and imaging to assess response
- Patient education and follow-up to ensure adherence and safety
These measures ensure effective immune activation while protecting healthy bladder tissue.
Treatment Process in Korea
The induction BCG therapy process includes:
- Pre-treatment evaluation with cystoscopy, imaging, and urine cytology
- TURBT, if necessary, to remove visible tumors
- Weekly BCG instillations over 6 weeks (typical induction schedule)
- Monitoring for side effects during treatment
- Post-induction cystoscopy to evaluate response and plan maintenance therapy
- Patient guidance on bladder care, hydration, and symptom management
International patients benefit from coordinated scheduling, multilingual support, and efficient outpatient care.
Recovery & After-Care
Recovery after induction BCG therapy is rapid as it is minimally invasive. Aftercare includes:
- Retaining BCG in the bladder for the prescribed dwell time (typically 2 hours)
- Staying hydrated to reduce bladder irritation
- Avoiding sexual activity and strenuous activity during dwell time
- Reporting severe urinary symptoms or high fever immediately
- Attending follow-up cystoscopies to assess treatment response
Korean hospitals often provide telemedicine support for international patients after returning home.
Results & Longevity
Induction BCG therapy in Korea demonstrates high success rates in eradicating residual NMIBC and reducing recurrence. Most patients retain bladder function and experience minimal systemic side effects. Successful induction therapy serves as a foundation for long-term maintenance therapy, improving overall survival and bladder preservation rates.
Why Korea Is a Top Destination
Korea is preferred for induction BCG therapy due to:
- Expertise in NMIBC immunotherapy and intravesical therapy protocols
- Advanced cystoscopic and drug delivery technology
- Integration with TURBT for comprehensive bladder cancer management
- Efficient outpatient treatment with minimal waiting times
- Multilingual coordination and support for international patients
- Cost-effective treatment compared to Western countries without compromising quality
Patients gain access to advanced treatment, high-quality care, and structured follow-up programs.
Cost Range
The cost of induction BCG therapy in Korea typically ranges from USD 1,500 to USD 4,000 per induction cycle, depending on:
- Hospital category and facility fees
- Combination with TURBT or additional diagnostic procedures
- Follow-up cystoscopies and imaging
- International patient support services
Korean hospitals provide transparent packages covering all essential treatment steps.
Popular Clinics in Korea
- Asan Medical Center – Urology & Bladder Cancer Clinic
- Seoul National University Hospital – NMIBC Immunotherapy Program
- Samsung Medical Center – BCG Induction Therapy Unit
- Severance Hospital (Yonsei University) – Bladder Cancer Center
- Korea University Anam Hospital – Outpatient Uro-Oncology Clinic
- Seoul St. Mary’s Hospital – BCG Therapy & Monitoring Clinic
